BMS-214662 activates PKCβ. (A) BMS-214662 (250nM) exposure caused a decrease in levels of PI3K, NF-κB, p-Akt, and Akt (i). Levels of E2F1 and NF-κB were compared after treatment for 24 hours with 250nM BMS-225975 or BMS-214662 (ii; n = 3). (B) Changes in PCKβ levels were analyzed by Western blotting after treatment with 250nM BMS-214662, 100nM bryostain-1, or a combination (i) and densitometry was performed (n = 3, ii). Treatment of normal CD34⁺ cells with BMS-214662 did not affect levels of PKCβ (iii). Treatment of CML CD34⁺ cells with BMS-225975 did not increase the level of PKCβ (iv). Error bars represent ± SD.